Comment on

• Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

  Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr, Franklin WA, Crowley J, Gandara DR; Southwest Oncology Group. Hirsch FR, et al. J Clin Oncol. 2005 Oct 1;23(28):6838-45. doi: 10.1200/JCO.2005.01.2823. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998906 Clinical Trial.
• Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.

  Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T. Takano T, et al. J Clin Oncol. 2005 Oct 1;23(28):6829-37. doi: 10.1200/JCO.2005.01.0793. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998907
• Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?

  Johnson BE, Jänne PA. Johnson BE, et al. J Clin Oncol. 2005 Oct 1;23(28):6813-6. doi: 10.1200/JCO.2005.97.008. Epub 2005 Sep 6. J Clin Oncol. 2005. PMID: 16145056 No abstract available.